

Has AI revolutionized drug discovery and clinical development?

Yochi Slonim

Company name: Anima Biotech Website: www.animabiotech.com

CEO name: Yochi Slonim

CATEGORY: Biotech/Pharma

- Is AI revolutionizing drug discovery and clinical development? Y

- o Executive Summary / Investment Rational Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths. Anima Biotech is a recognized leader in small molecule mRNA drugs. Backed by our strategic collaborations with Lilly, Takeda and Abbvie, our mRNA lightning™ platform is bringing AI to mRNA biology. With our proprietary visualization technologies, we have generated over 2 billion images of the mRNA life cycle in cells and train disease-specific image neural networks that visually recognize the mRNA regulatory pathways underlying disease mechanisms.

- o Core Technology What is the technology, its uniqueness, and its value proposition? Anima's mRNA Lightning platform is bringing AI to mRNA biology to advance the discovery of mRNA drugs, targets, and the optimization of vaccines and RNA-based drugs. Our differentiated approach is based on breakthrough mRNA biology imaging technologies that visualize the biology of mRNA across its life cycle in cells. This technology is applicable across a wide spectrum of applications in mRNA biology.

- o Product Profile/Pipeline Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships. Anima's wholly owned disclosed pipeline of mRNA biology modulators is in Immunology (Lung fibrosis candidate advancing in preclinical stage), in Oncology (Solid tumors lead compounds entering preclinical stage and additional programs against Lymphoma and Neuroblastoma), and in Neuroscience (Alzheimer's disease and Pain). In addition to our own pipeline, we established strategic collaborations with Pharma in partnered programs including our collaborations with Lilly, Takeda Pharmaceuticals, and Abbvie.